Impaired stock plunges as cancer drug studies are suspended after death

Affimed NV

AFMD, + 10.77%

The stock plunged late Monday night after a brief halt, the biotech drug developer having suspended two clinical trials after the death of one participant. Shares subscribed fell 28% after normal hours, after a gain of 11% to close at 4.63 dollars Monday. The company terminated two phase 1 or early clinical phases of its AFM11 cancer treatment following the death of one patient and the fact that two other patients had presented "life-threatening events." danger in the group receiving a high dose. Phase 1 studies evaluate the safety of an experimental drug. The studies tested the drug in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia types.

Have the latest news sent to your inbox. Subscribe to free e-mails from the MarketWatch newsletter. Register here.